Genome Editing and Gene Therapy

Pioneering biotech company Tocagen developed a cutting-edge, cancer-fighting gene therapy drug. As an experienced manufacturing partner, MilliporeSigma helps get the drug to patients quickly.

Collaboration in gene therapy

Gene therapy has been a scientific and medical goal since the early days of molecular biology. However, only recently have advances in the understanding of safety and efficacy of the viral vectors used to deliver genes for therapeutic purposes enabled the promise to become a reality. As the technology has improved, there has been a surge in efforts to use gene therapy to address some of the most challenging diseases.

A California dream

San Diego-based biotech company Tocagen has a vision of a world in which people don’t die of cancer. To achieve this goal, they are currently investigating a potential therapy to selectively deliver therapeutic genes into cancer cells. The gene carried by their lead product into cancer cells by a novel virus platform (gamma Retroviral Replicating Vector, RRV) is designed to produce a protein that converts an orally administered pro-drug into a potentially effective anti-cancer drug selectively within the virus-infected cell. This results in the activation of the immune system against the cancer by multiple mechanisms.

From the bench to trials

Tocagen’s lead product, which has recently received Breakthrough Therapy Designation from U.S. FDA for the treatment of recurrent high grade glioma (HGG) and Priority Medicines (PRIME) designation from the European Medicines Agency for the treatment of HGG, involves two discrete steps.  First, an investigational virus called Toca 511, which carries a therapeutic gene is injected into the residual tumor in the resection cavity wall immediately following surgical resection, or administered intravenously to patients with metastatic cancer. The virus is designed to integrate into the DNA of dividing cancer cells, which then serve as “factories“ for producing additional viruses. These new virus particles are then designed to spread to neighboring cancer cells, repeating the process and enabling long-term presence of the  therapeutic gene within the tumor. In the second step, patients take an investigational oral medication called Toca FC, which is designed to be activated only within infected cancer cells by expression of the therapeutic gene. 

After developing a production process in-house,  Tocagen needed a leader in the contract manufacturing of viral vaccines and gene therapy drug products to help them turn its innovative science into a viable, scalable approach that could potentially benefit many patients.  Manufacturing viruses for clinical trial supply and potentially commercial supply requires the ability to robustly scale production beyond what is required for earlier stages of clinical research.

Choosing a partner

“We wanted to work with scientists who were at the cutting edge of their field, who were committed to developing this therapy with us,” says Harry Gruber, president of science and innovation at Tocagen. MilliporeSigma met all of these requirements.

Harry Gruber, M.D., President, Science & Innovation at Tocagen

Harry Gruber , a medical doctor, who had worked with some of the original founders of the Carlsbad site earlier in his career. He therefore had a lot of confidence in their scientific ability and integrity.

MilliporeSigma shares our vision and our ideas. Together, we move quickly and come up with solutions to challenges.

Harry Gruber

M.D., President of Science & Innovation

Co-Founder of Tocagen

Five steps to this successful partnership

1. Open and honest communication

2. Develop an understanding of each other’s needs, capabilities, and vision for success

3. Ensure that all of the necessary resources are available to sustain the partnership in the long term

4. Commit to constant communication between all levels of the companies including executives so that everyone is on-board with the partnership vision

5. Be willing to share your success story internally and externally

Manufacturing the virus

As a contract manufacturing organization, MilliporeSigma's site in Carlsbad produces viral vectors for use in gene therapy or gene-modified cell therapeutics for clinical investigation. MilliporeSigma had already had experience with a number of different viruses and viral vectors and had become an expert in these areas, so Tocagen chose MilliporeSigma to begin manufacturing the virus at a large scale. 

Dave Backer, Head of Commercial Development, Genome Editing & Novel Therapies

The focus of Dave’s current role at MilliporeSigma has broadened tremendously. He is now supporting customers in advancing science through all kinds of gene and cell therapies, as well as with the coordination, maintenance, and expansion of the site’s manufacturing services and products.

We support our customers in their quest to develop safe and effective drug therapies.

Dave Backer

Head of Commercial Development, Genome Editing & Novel Modalities

MilliporeSigma

Finding the first signs

Tocagen has so far used the virus in three Phase 1 clinical studies and an ongoing Phase 3 trial. Of note, in those Phase 1 studies with human patients, they observed a favorable safety profile as well as  evidence of potential drug activity. Some of the data, initially reported in Science Translational Medicine, showed that multiple patients with recurrent brain cancer in the higher-dosage groups had durable complete tumor responses lasting multiple years . Based on these and other results, Tocagen is now conducting a pivotal Phase 3 trial and evaluating the treatment in patients with a wider range of tumor types. 

Asha Das, M.D., Senior Vice President & Chief Medical Officer, Tocagen

Asha Das is a medical doctor and the Senior Vice President and Chief Medical Officer at Tocagen. Her goal is to bring effective drugs to patients as quickly as possible. Her team writes protocols, conducts clinical studies, evaluates data, writes and submits publications – all of which are important to advance new medicines. 

Creating a manufacturing platform

Tocagen's and MilliporeSigma's relationship is based on a shared vision of an efficient gene therapy manufacturing platform that can make these therapeutics available to patients around the world. Their relationship serves as an example: Tocagen, with a novel platform for cancer immunotherapy and MilliporeSigma, with a deep expertise and long history in gene therapy and clinical trial manufacturing. For example, the teams have collaborated on many aspects of manufacturing including process optimization, automation, scaling, and validation planning. Together, the teams have successfully manufactured at clinical scale and are gearing up towards commercial supply.  The MilliporeSigma site was recently audited by both the FDA and EMA – a regulatory milestone that benefits both companies in their shared vision.

Building our capabilities and capacity in gene and cell therapy manufacturing is an investment in the future – and many companies that are developing these therapies might be able to benefit from it. Geographical proximity has certainly helped the two companies but was not a prerequisite for establishing a close relationship.

Martha Rook

Head of Genome Editing & Novel Modalities

Email

Partner With Us

To foster innovation and to keep providing cutting-edge science and technology for our customers, we collaborate closely with partners all over the world. We’re always seeking new opportunities to incorporate external ideas into our development portfolio.

Related Stories

View All Stories

Materials

Putting Mobility in the Fast Lane

Personal mobility has come a long way since someone had the bright idea to transform a piece of wood into a wheel. Join us on a quick trip down memory lane as we explore a high-tech future filled with smart ...

350

A welcome Ray of hope

An exciting complementary approach to cancer takes advantage of an ingenious natural defense: our own immune system.

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement